Innovent Biologics Inc logo

1801 - Innovent Biologics Inc News Story

HK$26.85 -0.2  -0.6%

Last Trade - 13/12/19

Sector
Healthcare
Size
Large Cap
Market Cap £3.29bn
Enterprise Value £3.00bn
Revenue £38.2m
Position in Universe 335th / 5953

BRIEF-Innovent Says Licensing Agreement With Lilly To Develop Novel Diabetes Medicine In China

Thu 22nd August, 2019 1:50am
Aug 21 (Reuters) - Innovent Biologics Inc  1801.HK :
    * INNOVENT ENTERS A LICENSING AGREEMENT WITH LILLY TO
DEVELOP &
COMMERCIALIZE A NOVEL DIABETES MEDICINE IN CHINA
    * INNOVENT BIOLOGICS- ENTERED LICENSING AGREEMENT WITH ELI
LILLY
FOR DEVELOPMENT AND POTENTIAL COMMERCIALIZATION OF OXYNTOMODULIN
ANALOG, OXM3, IN CHINA
    * FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED

Source text for Eikon:  ID:nPn4gdwLPa 
Further company coverage:  1801.HK 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.